AXL has previously been described to have broad tumor promoting functions, therefore several inhibitors of AXL have been developed for the clinic, such as R428 and sitravatinib, which we used to evaluate the role of AXL in driving resistance to ROS1 inhibition in CUTO33.20, 21. Here, ROS1 is linked to neoplasm.